Showing results (171-180 of 297) with videos related to
Sort By:
Pageof 30
Journal of Clinical Pharmacology|January 10, 2023
In Silico Re-Optimization of Atezolizumab Dosing Using Population Pharmacokinetic Simulation and Exposure-Response SimulationCody J Peer, Keith T Schmidt, Oluwatobi Arisa, et al.Human Molecular Genetics|June 1, 2014
Genetic factors affecting gene transcription and catalytic activity of UDP-glucuronosyltransferases in human liverWanqing Liu, Jacqueline Ramírez, Eric R Gamazon, et al.Pharmacogenetics and Genomics|January 21, 2006
Study of the genetic determinants of UGT1A1 inducibility by phenobarbital in cultured human hepatocytesJacqueline Ramírez, Bernard J Komoroski, Snezana Mirkov, et al.Cancer|December 24, 2003
A Phase II trial of suramin monthly x 3 for hormone-refractory prostate carcinomaNicholas J Vogelzang, Theodore Karrison, Walter M Stadler, et al.Journal of Clinical Pharmacology|December 29, 2006
The role of SN-38 exposure, UGT1A1*28 polymorphism, and baseline bilirubin level in predicting severe irinotecan toxicityRoshni P Ramchandani, Yaning Wang, Brian P Booth, et al.BMC Genomics|June 14, 2013
A genome-wide integrative study of microRNAs in human liverEric R Gamazon, Federico Innocenti, Rongrong Wei, et al.European Journal of Cancer (Oxford, England : 1990)|July 25, 2008
A phase I and pharmacokinetic study of the quinoxaline antitumour Agent R(+)XK469 in patients with advanced solid tumoursSamir D Undevia, Federico Innocenti, Jacqueline Ramirez, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 10, 2018
Do Patients With Advanced Cancer Have the Ability to Make Informed Decisions for Participation in Phase I Clinical Trials?Fay J Hlubocky, Greg A Sachs, Eric R Larson, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 15, 2002
Randomized study of three different doses of suramin administered with a fixed dosing schedule in patients with advanced prostate cancer: results of intergroup 0159, cancer and leukemia group B 9480Eric J Small, Susan Halabi, Mark J Ratain, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 24, 2009
Ambulatory monitoring detects sorafenib-induced blood pressure elevations on the first day of treatmentMichael L Maitland, Kristen E Kasza, Theodore Karrison, et al.Pageof 30